4568.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Stats
Dzisiejszy wolumen	5.32M
Średni wolumen	4.34M
Kapitalizacja rynkowa	10 550.08B
EPS	¥0 ( 2024-04-24 )
Następna data zysków	( ¥7.56 ) 2024-06-17
Last Dividend	¥15.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	52.63
ATR14	¥3.68 (0.07%)

Wolumen Korelacja

Długi: 0.22 (neutral)

Krótki: -0.55 (weak negative)

Signal:(42.089) Neutral

Daiichi Sankyo Company, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Daiichi Sankyo Company, Korelacja - Waluta/Towar

0.38
( neutral )

0.27
( neutral )

0.45
( neutral )

0.14
( neutral )

-0.44
( neutral )

-0.61
( weak negative )

Daiichi Sankyo Company, Finanse

Annual	2023
Przychody:	¥1 601.69B
Zysk brutto:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2023
Przychody:	¥1 601.69B
Zysk brutto:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2022
Przychody:	¥1 278.48B
Zysk brutto:	¥914.95B (71.57 %)
EPS:	¥56.96

FY	2022
Przychody:	¥1 044.89B
Zysk brutto:	¥691.56B (66.19 %)
EPS:	¥34.94

Financial Reports:

No articles found.

Daiichi Sankyo Company, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥15.00 (N/A)	¥0 (N/A)	¥15.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.79 - Stable (4.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.08	2000-03-28
Last Dividend	¥15.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥443.25	--
Avg. Dividend % Per Year	0.00%	--
Score	4.04	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.79
Div. Directional Score	8.60	--

Next Divdend (Est)
(2024-08-05)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

4.04

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8031.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7278.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6516.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5757.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
4540.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3030.T	Ex Dividend Junior	2024-02-28	Sporadic	0.00%
1909.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9882.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8925.T	No Dividend Player	2023-07-28	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.49	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0580	1.200	8.07	9.68	[0 - 0.3]
returnOnEquityTTM	0.125	1.500	9.72	10.00	[0.1 - 1]
payoutRatioTTM	0.335	-1.000	6.65	-6.65	[0 - 1]
currentRatioTTM	3.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.522	0.800	5.75	4.60	[0.8 - 2.5]
cashRatioTTM	0.895	1.500	6.14	9.21	[0.2 - 2]
debtRatioTTM	0.0294	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	11.63	1.000	6.80	6.80	[3 - 30]
operatingCashFlowPerShareTTM	312.59	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	248.54	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0603	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.741	1.000	0.988	0.988	[0.2 - 0.8]
operatingProfitMarginTTM	0.132	1.000	9.36	9.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.89	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.463	0.800	-0.248	-0.199	[0.5 - 2]
Total Score				12.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	52.55	1.000	4.79	0	[1 - 100]
returnOnEquityTTM	0.125	2.50	9.82	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	248.54	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.909	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	312.59	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.335	1.500	6.65	-6.65	[0 - 1]
pegRatioTTM	-4.87	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.374	1.000	3.15	0	[0.1 - 0.5]
Total Score				4.79

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.